September 2023—Global Access Diagnostics announced the launch of IT-Leish, a UKCA-marked rapid test used for diagnosing visceral leishmaniasis. The company acquired the manufacturing rights for IT-Leish from Bio-Rad in September 2022 to prevent the test’s withdrawal from the market and support the World Health Organization’s strategic plan to eliminate life-threatening neglected tropical diseases.
The test is a chromatographic in vitro diagnostic immunoassay for the qualitative detection of Leishmania spp.–specific antibodies in serum or capillary whole blood. Test results are generated in 20 minutes.
Global Access Diagnostics, 888-381-6870